Biography
Ashok Srivastava
Clinfomatrix Oncology, USA
Dr. Ashok Srivastava
is Chief Executive Officer and Chief Medical Officer of Cure Pharmaceuticals,
and ClinFomatrix Oncology CRO, He was founder, Chief Executive Officer and
Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New
Jersey. USA. He has more than 15 years of experience in drug development,
medical affairs and commercialization of cancer drugs including
radiopharmaceutical and supportive care; Phase 1 - 4, and marketing
commercialization of Hematology, Oncology and radio-immuno-oncology drugs in
USA, EU and Japan. He is leader in
Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials. He contributed to 21-INDs and 7-NDAs of
Cancer Drugs, acquisition /merger of company and drug for more than $900
million. He received his clinical, medical training & worked at renowned
medical centers and pharmaceutical institutions worldwide at various executive
leadership positions; Walter Reed Army Institute of Research and Medical
Center, Daiichi Pharmaceuticals, Sumitomo Pharmaceuticals, Pharmacia, Pfizer,
Eisai Oncology, Spectrum Pharmaceuticals and Taiho Oncology. He received his
Clinical, Medical & Business educations from All India Institute of Medical
Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School
of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers
University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology
drug - developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and
liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel
for HER2 positive for metastatic breast cancer patients and Latuda (Lurasidone)
for schizophrenia. He has published more than 85 papers in National and International Journals, more
than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous
National & International prestigious medical awards and recognitions from
United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed
Army Medical Center and Walter Reed Army Institute of Research, Washington DC,
USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung
cancer and Taiho Oncology in USA, EU and India. Dr. Srivastava is member of
numerous prestigious organizations; America's Top Oncologist of the years 2017,
Breast Cancer Foundation, Indian Society of Oncology, American Society of
Clinical Oncology, American Society for Therapeutic Radiology & Oncology,
American Association of Cancer Research, and International Society of Lung
Cancer. Dr. Srivastava is a strategic
medical advisor and Board Member to several pharma in USA for clinical,
regulatory and supervises cancer drug development. Recently Dr. Srivastava was
awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is
a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, immuno-oncology
and built global drug safety and pharmacovigilance companies in USA, and India.
Dr. Srivastava was invited as an honorable speaker at drug safety &
Pharmacovigilance congress in London, UK, India and Washington, DC, USA in
2017. Dr. Srivastava brought 2 cancer
drugs & a vaccine in global market for approximately 3 - 3.5 billion $ in global
sales. He serves as board of directors
for oncology pharma companies in USA.